Astegolimab

DRUG7 trials

Sponsors

F. Hoffmann-La Roche AG, Genentech, Inc., Hoffmann-La Roche, Hoffmann La Roche, F. Hoffmann La Roche Ltd

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Healthy VolunteersRespiratory

Phase 1

A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects

CompletedNCT06462118

Genentech, Inc.Healthy Volunteers

Start: 2024-06-17End: 2024-10-22Updated: 2025-01-30

Phase 2

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

CompletedNCT05037929

Genentech, Inc.Chronic Obstructive Pulmonary Disease

Start: 2021-10-05End: 2025-07-07Updated: 2026-02-25

Phase 3

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Active, not recruitingNCT05595642

Hoffmann-La RocheChronic Obstructive Pulmonary Disease (COPD)

Start: 2022-12-29End: 2027-09-24Target: 1290Updated: 2026-05-20

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

RecruitingPACTR202305580698795

Hoffmann La RocheRespiratory

Start: 2023-10-02Target: 1290Updated: 2026-08-03

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Active, not recruitingNCT05878769

Hoffmann-La RocheChronic Obstructive Pulmonary Disease

Start: 2023-06-28End: 2027-06-30Target: 2000Updated: 2026-08-14

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Active, not recruitingCTIS2022-502234-70-00

F. Hoffmann-La Roche AGChronic Obstructive Pulmonary Disease (COPD)

Start: 2023-07-14Target: 683Updated: 2025-08-26

A Phase III Open-Label Extension Study to Evaluate the Long-term Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease

Active, not recruitingPACTR202407572301048

F. Hoffmann La Roche LtdRespiratory

Start: 2024-11-01Target: 2000Updated: 2026-09-14

Related Papers

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

2026-05-18

Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials.

2026-05-18

ALIENTO and ARNASA: Study designs of two randomised, double-blind, placebo-controlled trials of astegolimab in patients with COPD

2023-09-092 citations